LABELS · 292f2c96-0e7f-7cf6-0106-4adfedc03423

BOSAYA

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-03-27
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Bosaya in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Bosaya in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD- MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Bosaya in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Bosaya in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bosaya is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Bosaya is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Bosaya is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Bosaya is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bosaya is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761436

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Bosaya in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Bosaya in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD- MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Bosaya in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Bosaya in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

brand names

BOSAYA

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e5e8c88-3c65-3076-e44b-02d92c2d343d

generic names

DENOSUMAB-KYQQ

292f2c96-0e7f-7cf6-0106-4adfedc03423

indications and usage exact

1 INDICATIONS AND USAGE Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bosaya is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Bosaya is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Bosaya is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Bosaya is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bosaya is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Biocon Biologics Inc.

matched search terms

cancer

package ndcs

83257-029-41

product ndcs

83257-029

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2725928
2725935

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761436

brand names

BOSAYA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 366
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 0

current approval status

not_reconciled

duplicate text group

dup-39942ba16526aa8a47fa

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-dc9c9ddea48255c46c80

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 166
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 447
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 0

current approval status

not_reconciled

duplicate text group

dup-dd905d8c128b7a890145

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-7eeb4c85f7f450400197

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 247
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 167

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761436

brand names

BOSAYA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 537
end exclusive: true
exact text: (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 48

current approval status

not_reconciled

duplicate text group

dup-e9fb1377f6e48a726540

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-c5d87e490600b6fe054d

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 337
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 248

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 673
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 138

current approval status

not_reconciled

duplicate text group

dup-2317472347f032f245eb

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-022818c5ff5374c87291

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 473
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 338

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 803
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bosaya is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 274

current approval status

not_reconciled

duplicate text group

dup-87cc364581df65464fab

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-12240316d44b6fb5b5c1

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 31

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
584
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start
541

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 603
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 474

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1165
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bosaya is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men wi
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 404

current approval status

not_reconciled

duplicate text group

dup-957c5dc6586604878742

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-897d34acf16555105451

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 705
end exclusive: true
exact text: is indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 693

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 965
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bosaya is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 604

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761436

brand names

BOSAYA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1319
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Bosaya is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteop
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 766

current approval status

not_reconciled

duplicate text group

dup-06b5d1c5fa312841621f

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-b1a73d636ebb81dc84e4

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1119
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 966

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1693
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Bosaya is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Bosaya is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating o
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 920

current approval status

not_reconciled

duplicate text group

dup-b34a6bb2630ac38530b5

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-4c7a8a28c05a692d3f10

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 1200
end exclusive: true
exact text: is indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1188

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1493
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Bosaya is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1120

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2059
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Bosaya is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1294

current approval status

not_reconciled

duplicate text group

dup-f0370a76ea900523b61e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-a3054cbfcde86c7c3a95

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 1566
end exclusive: true
exact text: is indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1554

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1859
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Bosaya is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1494

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761436

brand names

BOSAYA

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2286
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Bosaya is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androg
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1660

current approval status

not_reconciled

duplicate text group

dup-74d8d17c07df1d55de18

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-f53d0bd096cc2284e4dc

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2086
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1860

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2549
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Bosaya is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for B
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 1887

current approval status

not_reconciled

duplicate text group

dup-c9b892cd3fd75b7c8c06

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-52cbdefc9c81af4138f3

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 2199
end exclusive: true
exact text: is indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2187

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2349
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Bosaya is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2087

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761436

brand names

BOSAYA

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2660
end exclusive: true
exact text: n Therapy for Prostate Cancer Bosaya is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bosaya is indicated as a treatment to increase bone mass in women at high risk for fracture receiv
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2150

current approval status

not_reconciled

duplicate text group

dup-fee740a7e95934016ad4

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-21d73b494275f41da855

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2460
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2350

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761436

brand names

BOSAYA

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2751
end exclusive: true
exact text: fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bosaya is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2261

current approval status

not_reconciled

duplicate text group

dup-fd12a2bba2469194c71b

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-KYQQ

ind-span-7bdeb6034309a89ab831

label id

292f2c96-0e7f-7cf6-0106-4adfedc03423

positive predicate support span

end: 2581
end exclusive: true
exact text: is indicated
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2569

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bosaya is indicated as a treatment to increase b
kind
stage_or_setting
polarity
not_inferred
span
end
2550
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start
2507
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2707
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start
2664

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2751
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Bosaya is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: 292f2c96-0e7f-7cf6-0106-4adfedc03423
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 50827fbd2d388497b70acb063f2eab2b43f67d2f2e127ace1cb346b65e4a21b9
start: 2461

source url

https://api.fda.gov/drug/label.json?search=id%3A%22292f2c96-0e7f-7cf6-0106-4adfedc03423%22

spl effective date

2026-03-27

spl set id

1e5e8c88-3c65-3076-e44b-02d92c2d343d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice